| Revision as of 14:38, 10 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 460519360 of page Tuvirumab for the Chem/Drugbox validation project (updated: ''). |
Latest revision as of 20:58, 1 December 2023 edit Buidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,073 editsm Moving from Category:Experimental drugs to Category:Experimental antiviral drugs using Cat-a-lot |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
⚫ |
| verifiedrevid = 470618986 |
|
| Verifiedfields = changed |
|
| ⚫ |
| verifiedrevid = 447741911 |
|
|
| image = |
|
| image = |
|
|
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = |
|
| mab_type = |
|
| source = u |
|
| source = u |
|
| target = ] virus |
|
| target = ] virus |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
| Line 22: |
Line 19: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 29: |
Line 25: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ⚫ |
<!--Identifiers--> |
|
|
⚫ |
| ChemSpiderID = none |
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ⚫ |
| ChemSpiderID = NA |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = |
|
| CAS_number = 138660-97-6 |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
| Line 40: |
Line 35: |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
|
| UNII = 31Z0AB5WNC |
|
|
|
|
<!--Chemical data--> |
|
<!-- Chemical data --> |
|
| chemical_formula = |
|
| chemical_formula = |
|
| molecular_weight = |
|
| molecular_weight = |
|
}} |
|
}} |
|
|
|
|
|
'''Tuvirumab''' is a ] ] for the treatment of patients with chronic ]. It has undergone Phase I ] in 2001.<ref>{{cite journal | vauthors = Heijtink RA, van Nunen AB, van Bergen P, Ostberg L, Osterhaus AD, de Man RA | title = Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes | journal = Journal of Medical Virology | volume = 64 | issue = 4 | pages = 427–34 | date = August 2001 | pmid = 11468726 | doi = 10.1002/jmv.1068 | s2cid = 28825387 }}</ref><ref>{{cite journal | vauthors = van Nunen AB, Baumann M, Manns MP, Reichen J, Spengler U, Marschner JP, de Man RA | title = Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients | journal = Liver | volume = 21 | issue = 3 | pages = 207–12 | date = June 2001 | pmid = 11422784 | doi = 10.1034/j.1600-0676.2001.021003207.x | url = http://repub.eur.nl/pub/66667 | hdl = 1765/66667 | hdl-access = free }}</ref> |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
{{Monoclonals for infectious disease and toxins}} |
|
|
|
|
|
] |
|
|
] |
|
|
{{antiinfective-drug-stub}} |
|
|
{{monoclonal-antibody-stub}} |